Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of ORM-12741 Formulations
NCT02319057Phase 1Completed
- Sponsor
- Orion Corporation
- Start
- Sep 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ORM-12741 in Alzheimer's disease (AD) (6 arms), sponsored by Orion Corporation. Primary endpoint: Pharmacokinetics at Day 4. Started Sep 2014; status: completed.
02
Drugs
ORM-12741
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02319057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319057.